MBCProject_1037_T1_RNA
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.640
- INTERFERON_GAMMA_RESPONSE+0.590
- ALLOGRAFT_REJECTION+0.520
- IL6_JAK_STAT3_SIGNALING+0.450
- INFLAMMATORY_RESPONSE+0.300
- COMPLEMENT+0.290
- TNFA_SIGNALING_VIA_NFKB+0.280
- NOTCH_SIGNALING+0.260
- IL2_STAT5_SIGNALING+0.220
- P53_PATHWAY+0.150
Top 10 suppressed
- PROTEIN_SECRETION-0.420
- MYC_TARGETS_V1-0.360
- OXIDATIVE_PHOSPHORYLATION-0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- ESTROGEN_RESPONSE_EARLY-0.290
- MTORC1_SIGNALING-0.290
- ADIPOGENESIS-0.270
- ESTROGEN_RESPONSE_LATE-0.270
- MYC_TARGETS_V2-0.270
- BILE_ACID_METABOLISM-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1313132 | — | D | 0.874 |
| 2 | SRR8613774 | — | D | 0.873 |
| 3 | TCGA-AO-A0JC-01A-11R-A056-07 | — | D | 0.869 |
| 4 | SRR8613738 | — | D | 0.858 |
| 5 | AUR-AF95-TTP1-A-1-0-R-A741-41 | — | D | 0.853 |
| 6 | C3N-02675 | — | cohortSQ1 | 0.851 |
| 7 | TCGA-C8-A12V-01A-11R-A115-07 | — | D | 0.846 |
| 8 | TCGA-E9-A2JT-01A-22R-A18M-07 | — | D | 0.844 |
| 9 | SRR8518387 | — | D | 0.840 |
| 10 | TCGA-OR-A5JK-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.839 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.640 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.590 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.520 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.280 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.070 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |